Day: May 13, 2024

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debtSEATTLE, May 13, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer Key developments from Q1 2024 and the year to date include:Presented data from 40mg pharmacokinetic run-in cohort of ongoing EVANGELINE study at the AACR annual meeting...

Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in GA Expected in mid-2024 Clinical Proof of Concept (POC) Data for ANX1502, an Oral Classical Pathway Inhibitor for Chronic Autoimmune Conditions, on Track for Second Half of 2024 Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $264.9 Million as of March 31, 2024, and Anticipated Runway into mid-2026 BRISBANE, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Annexon, Inc....

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. “So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline final data...

Participants Are Welcome to Listen June 3rd at 9:00 am ET Waltham, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, announced today that it will release its financial results for the first quarter of 2024 before the Nasdaq market opens on Monday, June 3rd, 2024. Mr. Yoav Stern, Chief Executive Officer and Member of the Board of Directors, Mr. Tomer Pinchas, Chief Financial Officer & Chief Operating Officer, and Mr. Julien Lederman, VP of Corporate Development, of Nano Dimension will host a conference call on June 3rd, 2024, at 9:00 a.m. ET, to discuss the financial results. Participants can register for...

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors.Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Completed enrollment of patients in COMPANION-003, a Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC); top-line data from Stage 1 are expected by mid-year 2024. Enrollment in the Phase 1b combination study of CTX-471 (CD137 agonist antibody) and KEYTRUDA® in patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC)...

First Quarter Highlights ●  Revenue of $40.4 million, down 5.7% year-over-year (7.3% on a constant currency basis)●  Gross margin grew to 24.6%, a 270 bps increase sequentially and 250 bps increase year-over-year●  Net loss of $2.2 million includes $0.8 million of FX losses       ●  High margin Technology segment grew to 28.4% of revenues, a 120 bps increase sequentially and 690 bps increase year-over-year●  Awarded a multi-year contract with His Majesty’s Passport Office (“HMPO”) for a nationwide project in the UK with a Total Contract Value (“TCV”) of approximately $40 million LONDON and SANTA MONICA, Calif., May 13, 2024 (GLOBE NEWSWIRE) — XBP Europe Holdings, Inc. (“XBP Europe” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills, payments, and related solutions and services seeking to enable the digital transformation...

HALIFAX, Nova Scotia, May 13, 2024 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the three months ended March 31, 2024, and to provide an update on progress at its Bayan Khundii Gold Project (“BK” or “Project”), being developed with Mongolian Mining Corporation (“MMC”). This release should be read in conjunction with the Company’s Q1-2024 Condensed Consolidated Interim Financial Statements and MD&A, available on the Company’s website and SEDAR+. Peter Akerley, Erdene’s President and CEO stated, “During the first quarter, Erdene and MMC closed their Strategic Alliance and formally launched construction of the Bayan Khundii Gold Project, one of the highest grade, open pit gold mines under...